Alzheimer disease trials in Puerto Rico

In Puerto Rico 9 Also abroad 815

9 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Where
San Juan
Age
55 years to 90 years
People
426 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07011745 · EU 2025-520612-34-00
Phase 3Taking people
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Where
Bayamón
Age
55 years and over
People
550 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07602582
Phase 3Taking people
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Where
Bayamón, San Juan
Age
55 years to 90 years
People
406 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Where
San Juan
Age
60 years to 85 years
People
586 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06976216 · EU 2025-520746-30-00
Phase 3Taking people
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Where
San Juan
Age
50 years to 90 years
People
80,000 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07177352
Phase 3Taking people
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Where
Bayamón, Carolina, San Juan
Age
55 years to 90 years
People
1,000 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Where
Bayamón
Age
60 years to 85 years
People
586 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06976203 · EU 2025-520747-32-00
Phase 2/3Taking people
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Where
San Juan
Age
18 years and over
People
280 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT05552157
Phase 2/3Taking people
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Where
San Juan
Age
18 years and over
People
280 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT06647498